Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vemurafenib
Drug ID BADD_D02344
Description Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Indications and Usage Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
Marketing Status Prescription
ATC Code L01EC01
DrugBank ID DB08881
KEGG ID D09996
MeSH ID D000077484
PubChem ID 42611257
TTD Drug ID D0Y9EW
NDC Product Code 50242-090
Synonyms Vemurafenib | PLX4032 | PLX 4032 | RG7204 | RG-7204 | RG 7204 | Zelboraf | R05185426
Chemical Information
Molecular Formula C23H18ClF2N3O3S
CAS Registry Number 918504-65-1
SMILES CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Candida infection11.03.03.0210.000650%
Multiple organ dysfunction syndrome08.01.03.0570.000565%
Liver function test increased13.03.01.0440.001299%Not Available
Acanthosis23.01.04.0030.000866%Not Available
Adenocarcinoma of colon16.13.01.010; 07.21.01.0080.000433%Not Available
Brain neoplasm malignant16.30.04.002; 17.20.04.0020.000226%Not Available
Cellulitis orbital11.02.01.035; 06.04.11.0010.000433%Not Available
Intracranial tumour haemorrhage16.32.03.023; 24.07.04.028; 17.08.01.0520.000113%Not Available
Keratosis follicular23.01.01.006; 03.05.01.0190.000433%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000433%Not Available
Malignant melanoma in situ23.08.01.004; 16.03.01.0040.003248%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000113%Not Available
Palmoplantar keratoderma23.01.01.0070.002599%Not Available
Panniculitis lobular23.07.02.0050.000866%Not Available
Superficial spreading melanoma stage unspecified23.08.01.010; 16.03.01.0100.001083%Not Available
Lower extremity mass15.03.01.0150.000433%Not Available
Transient acantholytic dermatosis23.03.03.0690.001516%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000452%Not Available
Impaired self-care19.01.02.014; 08.01.03.0710.000866%Not Available
Fibrous histiocytoma23.10.01.012; 16.26.01.0120.000433%Not Available
Cell death14.11.02.005; 08.03.03.0030.000433%Not Available
Acantholysis23.03.03.0620.000866%Not Available
General physical condition abnormal13.15.01.0400.000433%Not Available
Acanthoma23.10.01.010; 16.26.01.0100.000113%Not Available
Dysplastic naevus23.10.01.011; 16.26.01.0110.000433%Not Available
Lip squamous cell carcinoma16.13.07.005; 07.21.07.0070.000650%Not Available
Neutrophilic panniculitis23.07.02.0040.002382%Not Available
Prerenal failure20.01.03.022; 24.06.02.0250.000433%Not Available
The 19th Page    First    Pre   19    Total 19 Pages